Don't want to speak for Dew by my thinking is they are dead because of side-effect or viral load reductions not being up to par with competitors compounds in Phase 1-2.
But VRTX doesn't have any clinical data in hand yet to make this call do they? Perhaps they just saw something pre-clinically that caused them to drop the compounds.
It would be huge for ITMN/Roche if BID Telaprevir is a flop and Ritonavir+191 allows for QD dosing (but I'll be happy with lower BID dosing).
That should certainly be a good advantage if all other things are at least equal. How much does Ritonavir add to the cost of treatment? Would 191+Ritonavir QD likely still be cheaper than telaprevir BID or TID?
Market Data 
Markets 
AI
